Cipla announced that the USFDA conducted a routine cGMP inspection at its API manufacturing facility in Virgonangar, Bengaluru, from 15 July 2019 to 19 July 2019.
The inspection ended with 7 observations, none of which were repeat or related to data integrity. The Company will respond to the agency within the stipulated timeline.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
